Agios/$AGIO
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Agios
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Ticker
$AGIO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
487
ISIN
US00847X1046
Website
Agios Metrics
BasicAdvanced
$2.1B
3.15
$11.45
0.73
-
Price and volume
Market cap
$2.1B
Beta
0.73
52-week high
$59.29
52-week low
$23.42
Average daily volume
579K
Financial strength
Current ratio
18.497
Quick ratio
17.124
Long term debt to equity
2.437
Total debt to equity
3.61
Profitability
EBITDA (TTM)
-434.711
Gross margin (TTM)
-737.13%
Net profit margin (TTM)
1,798.26%
Operating margin (TTM)
-1,188.86%
Effective tax rate (TTM)
6.23%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-22.88%
Return on equity (TTM)
60.26%
Valuation
Price to earnings (TTM)
3.149
Price to revenue (TTM)
55.589
Price to book
1.42
Price to tangible book (TTM)
1.42
Price to free cash flow (TTM)
-5.099
Free cash flow yield (TTM)
-19.61%
Free cash flow per share (TTM)
-707.43%
Growth
Revenue change (TTM)
25.96%
Earnings per share change (TTM)
-281.57%
3-year revenue growth (CAGR)
254.40%
10-year revenue growth (CAGR)
-8.61%
3-year earnings per share growth (CAGR)
21.22%
10-year earnings per share growth (CAGR)
24.16%
What the Analysts think about Agios
Analyst ratings (Buy, Hold, Sell) for Agios stock.
Bulls say / Bears say
Agios Pharmaceuticals' lead product, PYRUKYND® (mitapivat), generated $8.7 million in net revenue in Q1 2025, up from $8.2 million in Q1 2024, indicating steady growth in its commercial performance. (Agios Pharmaceuticals Press Release)
The European Commission granted orphan medicinal product designation to mitapivat for the treatment of sickle cell disease, providing benefits such as reduced fees and 10-year market exclusivity, which could enhance the drug's market potential in Europe. (StockTitan)
Analysts have shown confidence in Agios Pharmaceuticals, with Scotiabank raising its price target from $53.00 to $75.00 and assigning a 'sector outperform' rating, reflecting positive expectations for the company's future performance. (Defense World)
Agios Pharmaceuticals reported a net loss of $89.3 million for Q1 2025, compared to $81.5 million in Q1 2024, indicating increasing operational losses that may concern investors. (Agios Pharmaceuticals Press Release)
The departure of Dr. David P. Schenkein from the Board of Directors, effective February 28, 2025, could lead to uncertainties regarding the company's strategic direction and leadership stability. (Investing.com)
Insider selling activity, such as Chief Commercial Officer Tsveta Milanova selling 2,804 shares worth $90,232 in January 2025, might signal a lack of confidence in the company's short-term stock performance. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Agios Financial Performance
Revenues and expenses
Agios Earnings Performance
Company profitability
Agios News
AllArticlesVideos
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders
Business Wire·4 weeks ago
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
GlobeNewsWire·1 month ago
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Agios stock?
Agios (AGIO) has a market cap of $2.1B as of July 07, 2025.
What is the P/E ratio for Agios stock?
The price to earnings (P/E) ratio for Agios (AGIO) stock is 3.15 as of July 07, 2025.
Does Agios stock pay dividends?
No, Agios (AGIO) stock does not pay dividends to its shareholders as of July 07, 2025.
When is the next Agios dividend payment date?
Agios (AGIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Agios?
Agios (AGIO) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.